Drug Trial Radar · NCT06976177
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Jun 7, 2024
Primary completion
Aug 19, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013 after treatment.The treatment duration for Part A MAD study is 52 weeks and the duration for Part B study is 26 weeks.
Conditions
- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Interventions
MT1013Drug
MT1013 is a novel calcimimetic agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- The occurrence of adverse events within 26 weeksTime frame: Baseline up to 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.